Abstract | BACKGROUND/OBJECTIVES:
Glycopyrronium tosylate (GT) cloth, 2.4% is a topical anticholinergic approved in the United States for primary axillary hyperhidrosis in patients ≥9 years. This post hoc analysis evaluated long-term response (efficacy and safety) in pediatric patients (≥9 to ≤16 years) to GT in the 44-week, open-label extension (NCT02553798) of two, phase 3, double-blind, vehicle-controlled, 4-week trials (NCT02530281, NCT02530294). METHODS: In the double-blind trials, patients ≥9 years with primary axillary hyperhidrosis were randomized 2:1 to once-daily GT:vehicle. Those who completed the study could receive open-label GT for up to an additional 44 weeks. Safety assessments included treatment-emergent adverse events (TEAEs) and local skin reactions (LSRs). Descriptive efficacy assessments included gravimetrically measured sweat production, Hyperhidrosis Disease Severity Scale response (≥2-grade improvement), and Children's Dermatology Life Quality Index. RESULTS: Of 43 pediatric patients completing either double-blind trial, 38 (88.4%) entered the open-label extension (age, years: 9 [n = 1], 12 [n = 2], 13 [n = 7], 14 and 15 [n = 9 each], 16 [n = 10]). The safety profile observed was similar to the double-blind trials. Most TEAEs (>95%) were mild/moderate, related to anticholinergic activity, and infrequently led to discontinuation (n = 1/38 [2.6%]). No pediatric patients experienced a serious TEAE. Most anticholinergic TEAEs did not require a dose modification and resolved within 7 days. Approximately, one-third of patients (n = 13/38 [34.2%]) had LSRs; most were mild/moderate in severity. Improvements in efficacy measures were maintained from the double-blind trials. CONCLUSIONS: Long-term, once-daily GT for up to 48 weeks (4-week double-blind plus 44 week open label) provides a noninvasive, well-tolerated treatment option for pediatric patients with primary axillary hyperhidrosis.
|
Authors | Adelaide A Hebert, Dee Anna Glaser, Lawrence Green, Cheryl Hull, Jennifer Cather, Janice Drew, Ramanan Gopalan, David M Pariser |
Journal | Pediatric dermatology
(Pediatr Dermatol)
Vol. 37
Issue 3
Pg. 490-497
(May 2020)
ISSN: 1525-1470 [Electronic] United States |
PMID | 32147881
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2020 The Authors. Pediatric Dermatology published by Wiley Periodicals, Inc. |
Chemical References |
- Cholinergic Antagonists
- glycopyrronium tosylate
- Glycopyrrolate
|
Topics |
- Axilla
- Child
- Cholinergic Antagonists
- Double-Blind Method
- Glycopyrrolate
(adverse effects)
- Humans
- Hyperhidrosis
(drug therapy)
- Treatment Outcome
|